New Lawsuits Allege GLP-1 Drugs Cause Vision Loss
Lawsuits have been filed against manufacturers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, alleging that these medications caused vision loss, specifically non-arteritic anterior ischemic optic neuropathy (NAION). As of September 20, 2026, a U.S. personal injury law firm has filed more than 90 lawsuits in New Jersey state court on behalf of patients who developed NAION after taking Ozempic or Wegovy. A separate lawsuit has been filed in federal court in Philadelphiaarguing that GLP-1 drugs caused NAION and that drugmakers did not sufficiently warn of the associated risks. These legal actions highlight growing concerns regarding potential ocular side effects of these widely prescribed medications.
In December 2025, a new federal multidistrict litigation (MDL No. 3163) was established in the Eastern District of Pennsylvania to centralize federal lawsuits alleging GLP-1 drugs caused NAION vision loss. Judge Karen Marston is presiding over this MDL. As of July 2026, there were 146 pending cases in the NAION multidistrict litigation. A “Science Day” was held on June 2, 2026, where both sides presented scientific evidence on the link between GLP-1 drugs and NAION vision loss. The court will hear challenges to the parties’ expert witnesses from September 10, 18, 2026, in the gastrointestinal litigation related to GLP-1 drugs.
Official Statements and Expert Findings
The American Optometric Association (AOA) released a clinical report in July 2025, stating that NAION is among the rare ocular side effects of GLP-1RAs that can cause permanent vision loss. This report provides a significant medical perspective on the claims being made in the ongoing lawsuits. Manufacturers like Novo Nordisk, makers of Ozempic and Wegovy, and Eli Lilly, producers of Mounjaro, Zepbound, and Trulicity, have not yet issued public statements directly addressing the specifics of these new lawsuits. However, their product information typically includes extensive lists of potential side effects, which are subject to updates as new data emerges. For more information on the legal proceedings, interested parties can refer to coverage from outlets like ABC News, which initially reported on these claims.
Legal representatives for the plaintiffs assert that drugmakers failed to adequately inform patients and healthcare providers about the potential for NAION. They argue that had sufficient warnings been in place, patients might have made different treatment choices or sought earlier intervention for vision changes. The establishment of the federal multidistrict litigation shows the increasing number of similar claims and the need for a coordinated legal approach to address them efficiently.
Related: Three South Korean Officers Injured in DMZ Explosion
Background on GLP-1 Drugs and NAION
GLP-1 receptor agonists (GLP-1RAs) are a class of medications primarily used to treat type 2 diabetes and obesity. These drugs work by mimicking the effects of glucagon-like peptide-1, a hormone that helps regulate blood sugar levels and appetite. Popular GLP-1 drugs include Ozempic and Wegovy from Novo Nordisk, and Mounjaro, Zepbound, and Trulicity from Eli Lilly. These medications have gained significant popularity due to their effectiveness in weight management and glycemic control. The market for GLP-1 drugs has expanded rapidly, leading to widespread use globally.
Non-arteritic anterior ischemic optic neuropathy (NAION) is a sudden, painless loss of vision in one eye due to insufficient blood flow to the optic nerve. It is a leading cause of acute optic neuropathy in individuals over 50, though it can occur at any age. Risk factors for NAION typically include conditions that affect blood flow, such as diabetes, high blood pressure, high cholesterol, and sleep apnea. The connection between GLP-1 drugs and NAION is a subject of ongoing scientific and legal debate, with plaintiffs alleging a causal link and drug manufacturers likely defending their products’ safety profiles. The American Optometric Association’s clinical report, published in July 2025, represents a significant development in understanding the potential ocular risks associated with GLP-1RAs. This report highlights the importance of comprehensive patient counseling regarding all potential side effects, including rare but serious ocular complications. The legal proceedings in the Eastern District of Pennsylvania, overseen by Judge Karen Marstonwill be crucial in determining the extent of manufacturer liability and the future of warnings associated with these widely used medications.
Sources
Brands that want to grow their audience can work with 1889 Advertising.
